Eventide Asset Management boosted its stake in Viking Therapeutics, while Wedbush rated Voyager Therapeutics as 'outperform.'

Eventide Asset Management increased its stake in Viking Therapeutics by 200,000 shares, totaling 452,969 shares. Meanwhile, Wedbush initiated coverage on Voyager Therapeutics with an 'outperform' rating. Several hedge funds have adjusted their holdings in both companies, reflecting ongoing interest in biotech stocks. Viking Therapeutics' shares opened at $54.51, while Voyager's shares trade at $5.78 with a potential upside of 90.31% according to Wedbush's target price.

November 29, 2024
9 Articles

Further Reading